Adopts the solemn covenant of the states to award prizes for curing diseases interstate compact.
This bill would add a new article to the Public Health Law to authorize New York to join the “Solemn Covenant of the States to Award Prizes for Curing Diseases” interstate compact. The compact is designed to create a multi-state commission that would identify major diseases, evaluate submitted treatments or therapeutic protocols, and award monetary prizes to the first successful cure meeting the commission’s criteria. In exchange for a prize, the winner would generally transfer the patent and related intellectual property to the commission so the cure can be made widely available.
The commission would have broad authority to adopt bylaws and rules, set disease criteria, review submissions, conduct hearings and appeals, issue subpoenas, manage finances, borrow money, and coordinate manufacturing and distribution of cures. The compact also establishes a financing structure under which compacting states would pay annual dues and ultimately share in the prize obligation based on estimated public health savings from a cure. It includes provisions for royalty fees in non-compacting states and foreign countries, confidentiality of cure submissions, dispute resolution, compliance monitoring, withdrawal, default, expulsion, and dissolution of the compact.
If enacted, the bill would amend the Public Health Law by creating a new interstate compact article and binding New York to the compact’s governance, financing, and enforcement provisions once the compact becomes effective. It would authorize state participation in a commission that can adopt rules with the force of law in compacting states, require annual dues and potential prize-related appropriations, and establish mechanisms for prize payments, intellectual property transfer, and public availability of cures. The bill would also affect state fiscal and administrative practices by tying New York to multi-state obligations, possible bond financing, and compliance with commission rules and dispute processes.
The bill text and available context do not include committee debate or recorded votes, so there is no direct evidence of support or opposition from the legislative record provided. Based on the structure of the proposal, the bill appears to be framed as a public health innovation measure intended to incentivize cures for serious diseases through pooled state purchasing power and prize competition. The overall tone of the legislation is aspirational and pro-research, emphasizing access, savings in public health costs, and collaboration among states.
Potential points of contention include the breadth of authority given to the interstate commission, the requirement that prize winners transfer intellectual property, and the financial obligations imposed on participating states. The bill also raises questions about confidentiality of submissions, the commission’s immunity and indemnification provisions, and the extent to which state taxing power or full faith and credit may be implicated by prize funding and bond issuance. Another likely area of concern is the compact’s reliance on estimated public health savings and the possibility that non-compacting states and foreign jurisdictions could be subject to royalty-related provisions.